Havard Health Policy and Bioethics Consortium is holding a webinar.
The traditional model for drug development begins with publicly-funded science based in academic or government laboratories before private investors and for-profit pharmaceutical manufacturers become involved with their substantial expertise and resources. This for-profit drug development model has also been criticized for leaving certain public health issues unaddressed, particularly diseases prevalent in low-resource settings. What is the viability of other alternatives for funding drug discovery and development?
Date and Time:
Friday, March 13, 2020 - 09:45
More Info link: